No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study

• Main Authors: Yin-Qiu Huang (Author), Sheng-Quan Tang (Author), Xiao-Lei Xu (Author), Yan-Ming Zeng (Author), Xiao-Qing He (Author), Yao Li (Author), Vijay Harypursat (Author), Yan-Qiu Lu (Author), Yan Wan (Author), Lu Zhang (Author), Qiang-Zhong Sun (Author), Nan-Nan Sun (Author), Gui-Xue Wang (Author), Zhong-Ping Yang (Author), Yao-Kai Chen (Author)
• Format: Book
• Published: Frontiers Media S.A., 2020-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

BackgroundCurrently, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally, causing an unprecedented pandemic. However, there is no specific antiviral therapy for coronavirus disease 2019 (COVID-19). We conducted a clinical trial to compare the effectiveness of three antiv...